Teva Pharmaceuticals USA, Inc.

Company overview. Teva Pharmaceuticals USA, Inc. is the U.S. subsidiary of Teva Pharmaceutical Industries Ltd., the Israeli pharmaceutical group (NYSE/TASE: TEVA) founded in 1901 and headquartered in Tel Aviv. Teva USA, incorporated in 1985, houses the group's North American operations and moved its U.S. headquarters from North Wales, Pennsylvania, to Parsippany, New Jersey, around 2020. The parent is a public company with roughly 32,000–37,000 employees worldwide and annual revenue of about $16–17 billion (2021–2025), with a market cap in the low-to-mid $20 billion range in 2025.

Products / operations. Teva is the world's largest manufacturer of generic pharmaceuticals, with a portfolio of roughly 1,800 molecules. Teva USA manufactures and markets generic drugs in oral, injectable, and other dosage forms and distributes generic, biosimilar, and OTC products to retail pharmacies, chains, hospitals, and physician offices across the U.S. The group also sells innovative specialty medicines (including CNS products such as Austedo and Uzedy), biosimilars, and active pharmaceutical ingredients to third parties.

Patent-litigation posture. Teva is clearly an operating company, not an NPE: its two tracked appearances are classic Hatch-Waxman/ANDA disputes with Novartis. It appears once as a plaintiff-side petitioner — joining Actavis Elizabeth LLC in an inter partes review (IPR2017-01946) at the PTAB challenging Novartis's U.S. Patent 9,187,405 — and once as a defendant in Novartis Pharmaceuticals Corp. v. Teva Pharmaceuticals USA, Inc. in the District of Delaware, a venue common for ANDA suits (no Eastern District of Texas involvement). This two-way pattern is typical of a generic manufacturer both attacking and defending branded-drug patents.

Notable cases / context. The tracked cases center on Novartis's Gilenya (fingolimod) franchise: the IPR challenged the S1P-receptor-modulator patent covering a 0.5 mg daily dosing regimen for relapsing-remitting multiple sclerosis, and the Delaware suit was Novartis's ANDA infringement action tied to Teva's generic filing, which Teva answered with counterclaims. The IPR was joined with a parallel Apotex proceeding and appealed to the Federal Circuit; Teva's and Novartis's related disputes over the same franchise continued in later Delaware ANDA cases (e.g., 2022 and 2025 filings).